Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intraclass safety and efficacy comparison among SGLT-2 inhibitors in elderly patients with type 2 diabetes
2024-518915-20-00Phase 4Completed
- Sponsor
- Center for Outcomes Research and Clinical Epidemiology
- Start
- Feb 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of canagliflozin, dapagliflozin, empagliflozin, canagliflozin + metformin, dapagliflozin + metformin and 2 more in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Center for Outcomes Research and Clinical Epidemiology. Primary endpoint: Glucose control without level-3 hypoglycemia. Started Feb 2022; status: completed.
02
Drugs
canagliflozindapagliflozinempagliflozincanagliflozin + metformindapagliflozin + metformin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2024-518915-20-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518915-20-00.